Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog

Pharmacotherapy
Jerry Meece

Abstract

Despite the continued development of new pharmacologic agents, and the use of several existing drug therapies, almost two thirds of patients with type 2 diabetes mellitus do not reach the American Diabetes Association-targeted hemoglobin A(1c) level of less than 7.0%. Therefore, maintaining adequate metabolic control remains a primary concern for many clinicians and patients. It is now well recognized that in addition to defective secretion and action of insulin, other hormones also potentially play a role in the development and progression of type 2 diabetes. Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone from the incretin family, which stimulates insulin secretion and plays an important role in regulating the enteroinsular axis. Incretin-based therapies are the newest class of glucose-lowering drugs for the treatment of type 2 diabetes and may help address some of the unmet needs in this therapeutic area. Liraglutide is a once-daily GLP-1 analog that has been recently approved by the European Union regulatory agency and is in late-stage review by the United States Food and Drug Administration for the treatment of type 2 diabetes. The pharmacokinetic and pharmacodynamic properties of liraglutide and mechanisms b...Continue Reading

References

Apr 1, 1993·Digestive Diseases and Sciences·A WettergrenJ J Holst
Apr 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·M ShimabukuroR H Unger
Apr 8, 1999·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·E NäslundP M Hellström
Sep 14, 1999·The American Journal of Physiology·E NäslundP M Hellström
Dec 22, 2000·European Journal of Endocrinology·R Perfetti, P Merkel
Feb 7, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·R H Unger, L Orci
Mar 29, 2001·Diabetes·J H NielsenC Carlsson
Jun 7, 2003·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Henrik Agersø, Paolo Vicini
Nov 25, 2004·Diabetes·Gordon C Weir, Susan Bonner-Weir
Mar 31, 2005·Biochemical and Biophysical Research Communications·Søren BregenholtJacob S Petersen
Jul 20, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·M N FeinglosUNKNOWN Liraglutide Dose-Response Study Group
Mar 14, 2007·Endocrine Reviews·Bernardo L Wajchenberg
Jan 1, 2008·Diabetes·Niels Møller, K Sreekumaran Nair

❮ Previous
Next ❯

Citations

Sep 29, 2011·International Journal of Clinical Pharmacy·Kyeong-Hye Jeong, Bong Kyu Yoo
Aug 5, 2011·Diabetes, Obesity & Metabolism·B Ahrén, B Burke
Jan 12, 2012·Diabetes, Obesity & Metabolism·M S FinemanM Diamant
Dec 15, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Caslin A GilroyAshutosh Chilkoti
Nov 26, 2015·Clinical Pharmacokinetics·Lisbeth V JacobsenSteen H Ingwersen
May 5, 2010·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Nasser E Mikhail
Oct 27, 2015·Pharmacotherapy·Wesley A Nuffer, Jennifer M Trujillo
Jul 3, 2015·Therapeutic Advances in Endocrinology and Metabolism·Sri Harsha Tella, Marc S Rendell
Jan 1, 2011·Clinical Medicine Insights. Endocrinology and Diabetes·Kira R Brice, Maria K Tzefos
Nov 18, 2017·Interface Focus·Karolina L ZapadkaSophie E Jackson
Dec 4, 2019·Expert Opinion on Pharmacotherapy·Chen-Hsiu LinZhongmin Liu
Mar 31, 2021·Bioscience, Biotechnology, and Biochemistry·Chang WangXue-Gang Luo
Dec 24, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.